The nation's top vaccine advisory panel is expected to debate on Thursday whether to delay the first dose of the hepatitis B ...
1dOpinion
The Journey To Hepatitis B Elimination Through Innovation, Early Testing, And Scientific Discovery
As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...
The three-dose hepatitis B vaccine has a long track record of safety, but rolling back recommendations could leave kids ...
Hepatitis B vaccines given at birth have essentially eliminated the disease in kids. A vote this week could upend that ...
Richard Angell, CEO of the Terrence Higgins Trust, considers the success of opt-out HIV testing in A&E – and what it could ...
The CDC's Advisory Committee on Immunization Practices will discuss hepatitis b shots for newborns and updates to ...
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global ...
As RFK Jr.'s new vaccine panel ponders changing the hepatitis B vaccination schedule, some doctors recall past patients, ...
Mental health conditions are common among veterans and may play a larger role than previously recognized in raising liver cancer risk for those with hepatitis C.
The vaccine advisory committee of the Centers for Disease Control and Prevention is scheduled to meet Dec. 4 and 5. On the ...
December 2, 2025 - By Jackie Fortiér - Working out of a tribal-owned hospital in Anchorage, Alaska, liver specialist Brian ...
Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback